Europe Generic Drugs Market
Europe Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler) and Forecast, 2020-2026 Update Available - Forecast 2024-2030
Europe generic drugs market is estimated to grow at a CAGR of 5.7% during the forecast period. Some crucial factors encouraging market growth include the rising prevalence of chronic diseases and European government initiatives to increase the accessibility of generic drugs in the market. As per the International Diabetes Federation, in 2019, an estimated 59 million adults (20-79 years) were suffering from diabetes in Europe. This leads to an increasing demand for generic medicines for diabetes which include Glyburide, Glimepiride (Amaryl), and Glipizide. Further, Eli Lilly offers a generic version of Sanofi’s Lantus insulin, named Abasria insulin that is recommended for the treatment of diabetes.
The market is segmented based on application and route of administration. Based on application, the market is segmented into cancer, CVD, musculoskeletal diseases, infectious diseases, neurology, diabetes, and others. Rising cancer incidences and increasing EU launch of generics for cancer treatment are boosting the market growth. As per the World Health Organization (WHO), a total of 2.7 million new cancer (excluding non-melanoma skin cancers) incidences are estimated in 2020. This, in turn, drives the adoption of generic drugs owing to their cost-effectiveness and safety and efficacy. One of the instances is Pazenir which is a generic of Abraxane indicated for the treatment of non-small cell lung cancer (NSCLC) and metastatic breast cancer.
Some key players in the market include Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., and Novartis International AG. The market players are using some key strategies to increase their market share. For instance, in July 2019, Sandoz, a part of Novartis International AG declared the introduction of the generic cancer drug gefitinib which is intended for adult patients suffering from locally advanced or metastatic non-small cell lung cancer. It is available in 13 countries across Europe and the company will constantly widen to other countries through a phased rollout.
Research Methodology
The market study of the Europe generic drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
- Europe Generic Drugs Market Research and Analysis by Application
- Europe Generic Drugs Market Research and Analysis by Route of Administration
The Report Covers
- Comprehensive research methodology of the Europe generic drugs market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Europe generic drugs market.
- Insights about market determinants that are stimulating the Europe generic drugs market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Europe Generic Drugs Market by Application
5.1.1. Cancer
5.1.2. CVD
5.1.3. Musculoskeletal
5.1.4. Infectious Diseases
5.1.5. Neurology
5.1.6. Diabetes
5.1.7. Others
5.2. Europe Generic Drugs Market by Route of Administration
5.2.1. Oral
5.2.2. Topical
5.2.3. Injectable
5.2.4. Inhaler
6. Regional Analysis
6.1. UK
6.2. Germany
6.3. France
6.4. Spain
6.5. Italy
6.6. Rest of Europe
7. Company Profiles
7.1. Alvion Pharmaceuticals P.C
7.2. Fresenius SE & Co. KGaA
7.3. GlaxoSmithKline plc
7.4. Hikma Pharmaceuticals PLC
7.5. Lupin Ltd.
7.6. Mylan N.V.
7.7. Novartis International AG
7.8. Novo Nordisk A/S
7.9. StadaArzneimittel AG
7.10. Teva Pharmaceutical Industries Ltd.
1. EUROPE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
2. EUROPE GENERIC DRUGS IN CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
3. EUROPE GENERIC DRUGS IN CVD MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
4. EUROPE GENERIC DRUGS IN MUSCULOSKELETAL DISEASES RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
5. EUROPE GENERIC DRUGS IN INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
6. EUROPE GENERIC DRUGS IN NEUROLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
7. EUROPE GENERIC DRUGS IN DIABETES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
8. EUROPE GENERIC DRUGS IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
9. EUROPE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
10. EUROPE ORAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
11. EUROPE TOPICAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
12. EUROPE INJECTABLE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
13. EUROPE INHALER GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
14. EUROPE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
15. UK GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
16. UK GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
17. GERMANY GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
18. GERMANY GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
19. FRANCE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
20. FRANCE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
21. SPAIN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
22. SPAIN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
23. ITALY GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
24. ITALY GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
25. REST OF EUROPE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
26. REST OF EUROPE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
1. EUROPE GENERIC DRUGS MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
2. EUROPE GENERIC DRUGS IN CANCER MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. EUROPE GENERIC DRUGS IN CVD MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
4. EUROPE GENERIC DRUGS IN MUSCULOSKELETAL DISEASES MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
5. EUROPE GENERIC DRUGS IN INFECTIOUS DISEASES MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
6. EUROPE GENERIC DRUGS IN NEUROLOGY MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
7. EUROPE GENERIC DRUGS IN DIABETES MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
8. EUROPE GENERIC DRUGS IN OTHER APPLICATIONS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
9. EUROPE GENERIC DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2019 VS 2026 (%)
10. EUROPE ORAL GENERIC DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
11. EUROPE TOPICAL GENERIC DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
12. EUROPE INJECTABLE GENERIC DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
13. EUROPE INHALER GENERIC DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
14. EUROPE GENERIC DRUGS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
15. UK GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
16. GERMANY GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
17. FRANCE GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
18. SPAIN GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
19. ITALY GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
20. REST OF EUROPE GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
